BioSpace News Archive

Affini-T Therapeutics, Inc., today announced that the clinical strategy for enhancing the efficacy of its Merkel cell polyomavirus (MCPyV)-specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC), from its strategic collaboration with Fred Hutchinson Cancer Center, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022.

Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences.

Vaxart (NASDAQ: VXRT) today reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candidate in subjects aged 55 – 80 years (NCT04854746).

Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants ® program beginning on June 15, 2022.

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association.

Xenetic Biosciences, Inc. announced that it will participate in the Virtual Investor Innovation in Oncology Event on Thursday, June 9, 2022 at 11:00 AM ET.

Evofem Biosciences, Inc. announced that the U.S. Food and Drug Administration has formally extended the shelf life of Phexxi® from three to four years.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Jefferies Healthcare Conference being held June 8-10, 2022.